Gout: An old disease in new perspective - A review

Gaafar Ragab, Mohsen Elshahaly, Thomas Bardin, Gaafar Ragab, Mohsen Elshahaly, Thomas Bardin

Abstract

Gout is a picturesque presentation of uric acid disturbance. It is the most well understood and described type of arthritis. Its epidemiology is studied. New insights into the pathophysiology of hyperuricemia and gouty arthritis; acute and chronic allow for an even better understanding of the disease. The role of genetic predisposition is becoming more evident. The clinical picture of gout is divided into asymptomatic hyperuricemia, acute gouty arthritis, intercritical period, and chronic tophaceous gout. Diagnosis is based on laboratory and radiological features. The gold standard of diagnosis is identification of characteristic MSU crystals in the synovial fluid using polarized light microscopy. Imaging modalities include conventional radiography, ultrasonography, conventional CT, Dual-Energy CT, Magnetic Resonance Imaging, nuclear scintigraphy, and positron emission tomography. There is remarkable progress in the application of ultrasonography and Dual-Energy CT which is bound to influence the diagnosis, staging, follow-up, and clinical research in the field. Management of gout includes management of flares, chronic gout and prevention of flares, as well as management of comorbidities. Newer drugs in the pharmacological armamentarium are proving successful and supplement older ones. Other important points in its management include patient education, diet and life style changes, as well as cessation of hyperuricemic drugs.

Keywords: Clinical picture of gout; Gout; Hyperuricemia; Imaging modalities; Management of gout; Pathogenesis.

Figures

Graphical abstract
Graphical abstract
Fig. 1
Fig. 1
Pathogenesis of hyperuriceamia (perceived and designed by Dr. EL-Shahaly).
Fig. 2
Fig. 2
Renal excretion of uric acid (perceived and designed by Dr. EL-Shahaly).
Fig. 3
Fig. 3
Pathogenesis of acute gouty inflammation (perceived and designed by Dr. EL-Shahaly).
Fig. 4
Fig. 4
Chronic tophaceous gout: (a) hands, (b) ankle, (c) left greater toe (from the private collection of the authors).
Fig. 5
Fig. 5
Three examples of Ultrasonography in gout. (a) Intraarticular tophus, metatarsophalangeal joint; (b) Double contour sign; (c) Longitudinal image of extensor digitorum longus (EDL) tendon showing markedly distended sheath with synovial effusion, synovial hypertrophy and crystal aggregates (arrows) (Courtesy of Dr. Adham Aboul-Fotouh, Kasr Alainy Teaching Hospital, Cairo University).
Fig. 6
Fig. 6
DECT of a gouty patient showing two views of MSU deposits (in red) in the tibialis posterior tendon (from the private collection of prof. Bardin.
Fig. 7
Fig. 7
EULAR recommendation for the management of flares in patients with gout .
Fig. 8
Fig. 8
EULAR recommendation for the management of hyperuricemia in patients with gout .

References

    1. Dalbeth N., Merriman T.R., Stamp L.K. Gout Lancet. 2016;388(10055):2039–2052.
    1. Emmerson B.T. The management of gout. New Engl J Med. 1996;334(7):445–451.
    1. Pascual E., Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66(8):1056–1058.
    1. Singh J.A. Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol: Practical Rep Rheum Musculoskelet Dis. 2014;20(3):172–174.
    1. Kuo C.F., Grainge M.J., Zhang W., Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–662.
    1. McCarty D.J., Hollander J.L. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452–460.
    1. Mandal A.K., Mount D.B. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323–345.
    1. Kamei K., Konta T., Hirayama A., Suzuki K., Ichikawa K., Fujimoto S. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol, Dialysis, Transplant: official publication of the European Dialysis and Transplant Association – European Renal Association. 2014;29(12):2286–2292.
    1. Torres R.J., Puig J.G. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007;2:48.
    1. Reginato A.M., Olsen B.R. Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? Curr Opin Rheumatol. 2007;19(2):134–145.
    1. Kanbara A., Seyama I. Effect of urine pH on uric acid excretion by manipulating food materials. Nucleosides, Nucleotides Nucleic Acids. 2011;30(12):1066–1071.
    1. Towiwat P., Li Z.G. The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. Int J Rheum Dis. 2015;18(5):495–501.
    1. Mahmoud H.H., Leverger G., Patte C., Harvey E., Lascombes F. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer. 1998;77(Suppl 4):18–20.
    1. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57(9):509–510.
    1. Bedir A., Topbas M., Tanyeri F., Alvur M., Arik N. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J. 2003;44(4):527–536.
    1. Dessein P.H., Shipton E.A., Stanwix A.E., Joffe B.I., Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539–543.
    1. Ichida K., Matsuo H., Takada T., Nakayama A., Murakami K., Shimizu T. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nature Commun. 2012;3:764.
    1. Enomoto A., Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005;9(3):195–205.
    1. Bobulescu I.A., Moe O.W. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358–371.
    1. Han J., Liu Y., Rao F., Nievergelt C.M., O'Connor D.T., Wang X. Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Kidney Int. 2013;83(4):733–740.
    1. Cho S.K., Kim S., Chung J.Y., Jee S.H. Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1. BMJ Open. 2015;5(11):e009360.
    1. Tan P.K., Ostertag T.M., Miner J.N. Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep. 2016;6:34995.
    1. Phipps-Green A.J., Merriman M.E., Topless R., Altaf S., Montgomery G.W., Franklin C. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2016;75(1):124–130.
    1. Kolz M., Johnson T., Sanna S., Teumer A., Vitart V., Perola M. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5(6):e1000504.
    1. Liu R., O'Connell M., Johnson K., Pritzker K., Mackman N., Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum. 2000;43(5):1145–1155.
    1. Cronstein B.N., Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol: Practical Rep Rheumat Musculoskelet Dis. 2013;19(1):19–29.
    1. Busso N., Ea H.K. The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis) Reumatismo. 2012;63(4):230–237.
    1. Ea H.K. Mechanisms of gout inflammation. Presse Med. 2011;40(9 Pt 1):836–843.
    1. Dalbeth N., Lauterio T.J., Wolfe H.R. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465–1479.
    1. Steiger S., Harper J.L. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep. 2014;16(1):392.
    1. Grassi W., De Angelis R. Clinical features of gout. Reumatismo. 2012;63(4):238–245.
    1. Gonzalez E.B. An update on the pathology and clinical management of gouty arthritis. Clin Rheumatol. 2012;31(1):13–21.
    1. Schlesinger N., Thiele R.G. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010;69(11):1907–1912.
    1. Kosmadakis G., Viskaduraki M., Michail S. The validity of fractional excretion of uric acid in the diagnosis of acute kidney injury due to decreased kidney perfusion. Am J Kidney Dis. 2009;54(6):1186–1187.
    1. Burns C.M., Wortmann R.L. Latest evidence on gout management: what the clinician needs to know. Therap Adv Chronic Dis. 2012;3(6):271–286.
    1. Kanbay M., Huddam B., Azak A., Solak Y., Kadioglu G.K., Kirbas I. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol: CJASN. 2011;6(8):1887–1894.
    1. Luk A.J., Levin G.P., Moore E.E., Zhou X.H., Kestenbaum B.R., Choi H.K. Allopurinol and mortality in hyperuricaemic patients. Rheumatol (Oxford, England) 2009;48(7):804–806.
    1. Yokose C., Chen M., Berhanu A., Pillinger M.H., Krasnokutsky S. Gout and osteoarthritis: associations, pathophysiology, and therapeutic implications. Curr Rheumatol Rep. 2016;18(10):65.
    1. Mazzali M., Kanbay M., Segal M.S., Shafiu M., Jalal D., Feig D.I. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep. 2010;12(2):108–117.
    1. Katsiki N., Papanas N., Fonseca V.A., Maltezos E., Mikhailidis D.P. Uric acid and diabetes: Is there a link? Curr Pharm Des. 2013;19(27):4930–4937.
    1. Roddy E. Revisiting the pathogenesis of podagra: why does gout target the foot? J Foot Ankle Res. 2011;4(1):13.
    1. Canoso J.J., Yood R.A. Acute gouty bursitis: report of 15 cases. Ann Rheum Dis. 1979;38(4):326–328.
    1. Perez-Ruiz F., Castillo E., Chinchilla S.P., Herrero-Beites A.M. Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am. 2014;40(2):193–206.
    1. Pascual E., Batlle-Gualda E., Martinez A., Rosas J., Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131(10):756–759.
    1. Chhana A., Dalbeth N. The gouty tophus: a review. Curr Rheumatol Rep. 2015;17(3):19.
    1. Malik A., Schumacher H.R., Dinnella J.E., Clayburne G.M. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol: Practical Rep Rheum Musculoskelet Dis. 2009;15(1):22–24.
    1. Zhang W., Doherty M., Pascual E., Bardin T., Barskova V., Conaghan P. EULAR evidence based recommendations for gout. Part I: diagnosis. report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) Ann Rheum Dis. 2006;65(10):1301–1311.
    1. Atdjian M., Fernandez-Madrid F. Coexistence of chronic tophaceous gout and rheumatoid arthritis. J Rheumatol. 1981;8(6):989–992.
    1. Dincer H.E., Dincer A.P., Levinson D.J. Asymptomatic hyperuricemia: to treat or not to treat. Clevel Clin J Med. 2002;69(8):594. 7, 600-2 passim.
    1. Badulescu M., Macovei L., Rezus E. Acute gout attack with normal serum uric acid levels. Rev Med Chir Soc Med Nat Iasi. 2014;118(4):942–945.
    1. Underwood M. Diagnosis and management of gout. BMJ (Clin Res Ed) 2006;332(7553):1315–1319.
    1. Pascual E., Tovar J., Ruiz M.T. The ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluid. Ann Rheum Dis. 1989;48(12):983–985.
    1. Phelps P., Steele A.D., McCarty D.J., Jr. Compensated polarized light microscopy. Identification of crystals in synovial fluids from gout and pseudogout. JAMA. 1968;203(7):508–512.
    1. Strasinger S.K., Di Lorenzo M.S. F. A. Davis Company; 2008. Urinalysis & body fluids.
    1. Kramer H.M., Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis. 2002;40(1):37–42.
    1. Fernandes EA, Bergamaschi SB, Rodrigues TC, Dias GC, Malmann R, Ramos GM, et al. Relevant aspects of imaging in the diagnosis and management of gout. Revista brasileira de reumatologia. 2016.
    1. Rettenbacher T., Ennemoser S., Weirich H., Ulmer H., Hartig F., Klotz W. Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray. Eur Radiol. 2008;18(3):621–630.
    1. Namas R., Meysami A., Siegal D., Rubin B. Gout and ultrasound: the disease of kings and the queen of imaging. Gout Hyperuricaemia. 2014;1:94–100.
    1. Bloch C., Hermann G., Yu T.F. A radiologic reevaluation of gout: a study of 2,000 patients. AJR Am J Roentgenol. 1980;134(4):781–787.
    1. Malghem J, Vande Berg B, Lecouvet F. Goutte d’hier et d’aujourd’hui. Imagerie de l’appareil musculo-squlettique: Textes choisis. Montpellier (France): Sauramps Medical; 2011. p. 35–44.
    1. Omoumi P., Zufferey P., Malghem J., So A. Imaging in gout and other crystal-related arthropathies. Rheum Dis Clin North Am. 2016;42(4):621–644.
    1. Martel W. The overhanging margin of bone: a roentgenologic manifestation of gout. Radiology. 1968;91(4):755–756.
    1. Gentili A. Advanced imaging of gout. Semin Musculoskelet Radiol. 2003;7(3):165–174.
    1. Choi M.H., MacKenzie J.D., Dalinka M.K. Imaging features of crystal-induced arthropathy. Rheum Dis Clin North Am. 2006;32(2):427–446. viii.
    1. Gentili A. The advanced imaging of gouty tophi. Curr Rheumatol Rep. 2006;8(3):231–235.
    1. Durcan L., Grainger R., Keen H.I., Taylor W.J., Dalbeth N. Imaging as a potential outcome measure in gout studies: A systematic literature review. Semin Arthritis Rheum. 2016;45(5):570–579.
    1. Dalbeth N., Clark B., McQueen F., Doyle A., Taylor W. Validation of a radiographic damage index in chronic gout. Arthritis Rheum. 2007;57(6):1067–1073.
    1. Nestorova R., Fodor D. Crystal-induced arthritis. In: El Miedany Y., editor. Musculoskeletal ultrasonography in rheumatic diseases. Springer International Publishing; Cham: 2015. pp. 137–167.
    1. Grassi W., Gutierrez M., Filippucci E. Chapter 16 - crystal-associated synovitis A2 – Wakefield, Richard J. In: D'Agostino M.A., editor. Essential applications of musculoskeletal ultrasound in rheumatology. Content Repository Only!; Philadelphia: 2010. pp. 187–197.
    1. Filippucci E., Di Geso L., Grassi W. Tips and tricks to recognize microcrystalline arthritis. Rheumatol (Oxford, England) 2012;51(Suppl 7):vii18–vii21.
    1. Gutierrez M., Smith W., Thiele R., Keen H., Kaeley G., Naredo E. Defining elementary ultrasound lesions in gout. Preliminary results of Delphi consensus and web-exercise reliability. Ann Rheum Dis. 2014;73(Suppl 2):302.
    1. Wright S.A., Filippucci E., McVeigh C., Grey A., McCarron M., Grassi W. High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. Ann Rheum Dis. 2007;66(7):859–864.
    1. Filippucci E., Riveros M.G., Georgescu D., Salaffi F., Grassi W. Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthr Cartilage. 2009;17(2):178–181.
    1. Thiele R.G., Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2010;30(4):495–503.
    1. Thiele R.G., Schlesinger N. Diagnosis of gout by ultrasound. Rheumatol (Oxford, England) 2007;46(7):1116–1121.
    1. Naredo E., Uson J., Jimenez-Palop M., Martinez A., Vicente E., Brito E. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis. 2014;73(8):1522–1528.
    1. Abate M., Schiavone C., Salini V., Andia I. Occurrence of tendon pathologies in metabolic disorders. Rheumatol (Oxford, England) 2013;52(4):599–608.
    1. Dalbeth N., Clark B., Gregory K., Gamble G., Sheehan T., Doyle A. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis. 2009;68(8):1290–1295.
    1. McQueen F.M., Doyle A., Dalbeth N. Imaging in gout–what can we learn from MRI, CT, DECT and US? Arthritis Res Therapy. 2011;13(6):246.
    1. Gerster J.C., Landry M., Dufresne L., Meuwly J.Y. Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis. 2002;61(1):52–54.
    1. Dalbeth N., Clark B., Gregory K., Gamble G.D., Doyle A., McQueen F.M. Computed tomography measurement of tophus volume: Comparison with physical measurement. Arthritis Care Res. 2007;57(3):461–465.
    1. Perez-Ruiz F., Calabozo M., Pijoan J.I., Herrero-Beites A.M., Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Care Res. 2002;47(4):356–360.
    1. Gerster J.C., Landry M., Duvoisin B., Rappoport G. Computed tomography of the knee joint as an indicator of intraarticular tophi in gout. Arthritis Rheum. 1996;39(8):1406–1409.
    1. Omoumi P., Becce F., Ott J.G., Racine D., Verdun F.R. Optimization of radiation dose and image quality in musculoskeletal CT: emphasis on iterative reconstruction techniques (Part 1) Semin Musculoskelet Radiol. 2015;19(5):415–421.
    1. Omoumi P., Verdun F.R., Becce F. Optimization of radiation dose and image quality in musculoskeletal CT: emphasis on iterative reconstruction techniques (Part 2) Semin musculoskelet Radiol. 2015;19(5):422–430.
    1. Omoumi P., Becce F., Racine D., Ott J.G., Andreisek G., Verdun F.R. Dual-Energy CT: basic principles, technical approaches, and applications in musculoskeletal imaging (Part 1) Semin Musculoskelet Radiol. 2015;19(5):431–437.
    1. Nicolaou S. Invited commentary. Radio Graph. 2011;31(5):1376–1377.
    1. Huppertz A., Hermann K.G., Diekhoff T., Wagner M., Hamm B., Schmidt W.A. Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int. 2014;34(6):763–771.
    1. Bongartz T., Glazebrook K.N., Kavros S.J., Murthy N.S., Merry S.P., Franz W.B., 3rd Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis. 2015;74(6):1072–1077.
    1. Melzer R., Pauli C., Treumann T., Krauss B. Gout tophus detection-a comparison of dual-energy CT (DECT) and histology. Semin Arthritis Rheum. 2014;43(5):662–665.
    1. McQueen F.M., Doyle A.J., Reeves Q., Gamble G.D., Dalbeth N. DECT urate deposits: now you see them, now you don't. Ann Rheum Dis. 2013;72(3):458–459.
    1. Glazebrook K.N., Guimaraes L.S., Murthy N.S., Black D.F., Bongartz T., Manek N.J. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261(2):516–524.
    1. Chowalloor P.V., Siew T.K., Keen H.I. Imaging in gout: A review of the recent developments. Therap Adv Musculoskelet Dis. 2014;6(4):131–143.
    1. Toprover M., Krasnokutsky S., Pillinger M.H. Gout in the spine: imaging, diagnosis, and outcomes. Curr Rheumatol Rep. 2015;17(12):70.
    1. Zheng Z.F., Shi H.L., Xing Y., Li D., Jia J.Y., Lin S. Thoracic cord compression due to ligamentum flavum gouty tophus: a case report and literature review. Spinal Cord. 2015;53(12):881–886.
    1. Nunes E.A., Rosseti A.G., Jr., Ribeiro D.S., Santiago M. Gout initially mimicking rheumatoid arthritis and later cervical spine involvement. Case Rep Rheumatol. 2014;2014:357826.
    1. Ahmad I., Tejada J.G. Spinal gout: a great mimicker. A case report and literature review. Neuroradiol J. 2012;25(5):621–625.
    1. Nygaard H.B., Shenoi S., Shukla S. Lower back pain caused by tophaceous gout of the spine. Neurology. 2009;73(5):404.
    1. Hsu C.Y., Shih T.T., Huang K.M., Chen P.Q., Sheu J.J., Li Y.W. Tophaceous gout of the spine: MR imaging features. Clin Radiol. 2002;57(10):919–925.
    1. Gongidi P., Gough-Fibkins S. Spondyloarthritis: a gouty display. J Radiol Case Rep. 2010;4(5):13–18.
    1. Zhao Z., Wang Y., Jin J., Deng X., Huang F. An analysis of abnormal magnetic resonance imaging of sacroiliac joints in patients misdiagnosed as spondyloarthritis. Zhonghua nei ke za zhi. 2014;53(9):724–729.
    1. Kang H.J., Jung S.H., Yoon H.K., Hahn S.B., Kim S.J. Carpal tunnel syndrome caused by space occupying lesions. Yonsei Med J. 2009;50(2):257–261.
    1. Chen C.K., Chung C.B., Yeh L., Pan H.B., Yang C.F., Lai P.H. Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients. AJR Am J Roentgenol. 2000;175(3):655–659.
    1. Godfrin-Valnet M., Godfrin G., Godard J., Prati C., Toussirot E., Michel F. Eighteen cases of crowned dens syndrome: Presentation and diagnosis. Neurochirurgie. 2013;59(3):115–120.
    1. Udayakumar D., Kteleh T., Alfata S., Bali T., Joseph A. Spinal gout mimicking paraspinal abscess: A case report. J Radiol Case Rep. 2010;4(6):15–20.
    1. Chen C.H., Chen C.K., Yeh L.R., Pan H.B., Yang C.F. Intra-abdominal gout mimicking pelvic abscess. Skeletal Radiol. 2005;34(4):229–233.
    1. Grainger R., Dalbeth N., Keen H., Durcan L., Lawrence Edwards N., Perez-Ruiz F. Imaging as an outcome measure in gout studies: report from the OMERACT gout working group. J Rheumatol. 2015;42(12):2460–2464.
    1. Dalbeth N., Choi H.K., Terkeltaub R. Review: gout: a roadmap to approaches for improving global outcomes. Arthritis Rheumatol. 2017;69(1):22–34.
    1. Doherty M., Jansen T.L., Nuki G., Pascual E., Perez-Ruiz F., Punzi L. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765–1770.
    1. Khanna D., Fitzgerald J.D., Khanna P.P., Bae S., Singh M.K., Neogi T. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64(10):1431–1446.
    1. Khanna D., Khanna P.P., Fitzgerald J.D., Singh M.K., Bae S., Neogi T. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64(10):1447–1461.
    1. Richette P., Doherty M., Pascual E., Barskova V., Becce F., Castaneda-Sanabria J. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.
    1. De Vera M.A., Marcotte G., Rai S., Galo J.S., Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken) 2014;66(10):1551–1559.
    1. Terkeltaub R.A., Furst D.E., Bennett K., Kook K.A., Crockett R.S., Davis M.W. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068.
    1. Terkeltaub R.A., Furst D.E., Digiacinto J.L., Kook K.A., Davis M.W. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226–2237.
    1. Boonmuang P., Nathisuwan S., Chaiyakunapruk N., Suwankesawong W., Pokhagul P., Teerawattanapong N. Characterization of statin-associated myopathy case reports in Thailand using the health product vigilance center database. Drug Saf. 2013;36(9):779–787.
    1. Kuncl R.W., Duncan G., Watson D., Alderson K., Rogawski M.A., Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562–1568.
    1. Janssens H.J., Janssen M., van de Lisdonk E.H., van Riel P.L., van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854–1860.
    1. Man C.Y., Cheung I.T., Cameron P.A., Rainer T.H. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49(5):670–677.
    1. Rainer T.H., Cheng C.H., Janssens H.J., Man C.Y., Tam L.S., Choi Y.F. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164(7):464–471.
    1. Richette P., Bardin T. Should prednisolone be first-line therapy for acute gout? Lancet. 2008;372(9646):1301. author reply -2.
    1. Daoussis D., Antonopoulos I., Yiannopoulos G., Andonopoulos A.P. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine. 2013;80(3):291–294.
    1. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
    1. Ottaviani S., Molto A., Ea H.K., Neveu S., Gill G., Brunier L. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123.
    1. Schlesinger N., Alten R.E., Bardin T., Schumacher H.R., Bloch M., Gimona A. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–1848.
    1. Qaseem A., Harris R.P., Forciea M.A. Management of acute and recurrent gout: a clinical practice guideline from the american college of physicians. Ann Intern Med. 2017;166(1):58–68.
    1. Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826–830.
    1. Dalbeth N., Wong S., Gamble G.D., Horne A., Mason B., Pool B. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010;69(9):1677–1682.
    1. Zhu Y., Zhang Y., Choi H.K. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford) 2010;49(12):2391–2399.
    1. Beyl R.N., Jr., Hughes L., Morgan S. Update on importance of diet in gout. Am J Med. 2016;129(11):1153–1158.
    1. Azadbakht L., Mirmiran P., Esmaillzadeh A., Azizi T., Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care. 2005;28(12):2823–2831.
    1. Kontogianni M.D., Chrysohoou C., Panagiotakos D.B., Tsetsekou E., Zeimbekis A., Pitsavos C. Adherence to the Mediterranean diet and serum uric acid: the ATTICA study. Scand J Rheumatol. 2012;41(6):442–449.
    1. Kiltz U., Smolen J., Bardin T., Cohen Solal A., Dalbeth N., Doherty M. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2016
    1. Latourte A., Bardin T., Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford) 2014;53(11):1920–1926.
    1. Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–410.
    1. Richette P., Perez-Ruiz F., Doherty M., Jansen T.L., Nuki G., Pascual E. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654–661.
    1. Roberts C.J., Marshall A.J., Heaton S., Barritt D.W. Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone. BMJ. 1979;1(6158):224–226.
    1. Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78(5):456–459.
    1. Greene M.L., Fujimoto W.Y., Seegmiller J.E. Urinary xanthine stones–a rare complications of allopurinol therapy. N Engl J Med. 1969;280(8):426–427.
    1. Wright D.F., Duffull S.B., Merriman T.R., Dalbeth N., Barclay M.L., Stamp L.K. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81(2):277–289.
    1. Roberts R.L., Wallace M.C., Phipps-Green A.J., Topless R., Drake J.M., Tan P. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2016
    1. Annemans L., Spaepen E., Gaskin M., Bonnemaire M., Malier V., Gilbert T. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67(7):960–966.
    1. Delbarre F., Amor B., Auscher C., de Gery A. Treatment of gout with allopurinol. A study of 106 cases. Ann Rheum Dis. 1966;25(6 Suppl):627–633.
    1. Becker M.A., Schumacher H.R., Jr, Wortmann R.L., MacDonald P.A., Eustace D., Palo W.A. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–2461.
    1. Schumacher H.R., Jr, Becker M.A., Wortmann R.L., Macdonald P.A., Hunt B., Streit J. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548.
    1. Becker M.A., Fitz-Patrick D., Choi H.K., Dalbeth N., Storgard C., Cravets M. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015;45(2):174–183.
    1. Reinders M.K., van Roon E.N., Jansen T.L., Delsing J., Griep E.N., Hoekstra M. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68(1):51–56.
    1. Tam S., Carroll W. Allopurinol hepatotoxicity. Am J Med. 1989;86(3):357–358.
    1. Greenberg M.S., Zambrano S.S. Aplastic agranulocytosis after allopurinol therapy. Arthritis Rheum. 1972;15(4):413–416.
    1. Gelbart D.R., Weinstein A.B., Fajardo L.F. Allopurinol-induced interstitial nephritis. Ann Intern Med. 1977;86(2):196–198.
    1. Azulay J.P., Blin O., Valentin P., Abegg P., Pellissier J.F., Serratrice G. Regression of allopurinol-induced peripheral neuropathy after drug withdrawal. Eur Neurol. 1993;33(3):193–194.
    1. Sidoroff A., Halevy S., Bavinck J.N., Vaillant L., Roujeau J.C. Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113–119.
    1. Bastuji-Garin S., Rzany B., Stern R.S., Shear N.H., Naldi L., Roujeau J.C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–96.
    1. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., Halevy S., Davidovici B.B., Mockenhaupt M. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609–611.
    1. Kim S.C., Newcomb C., Margolis D., Roy J., Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken) 2013;65(4):578–584.
    1. Yang C.Y., Chen C.H., Deng S.T., Huang C.S., Lin Y.J., Chen Y.J. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 2015;175(9):1550–1557.
    1. Hung S.I., Chung W.H., Liou L.B., Chu C.C., Lin M., Huang H.P. HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–4139.
    1. Ng C.Y., Yeh Y.T., Wang C.W., Hung S.I., Yang C.H., Chang Y.C. Impact of the HLA-B(∗)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol. 2016;136(7):1373–1381.
    1. Stamp L.K., Taylor W.J., Jones P.B., Dockerty J.L., Drake J., Frampton C. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529–2536.
    1. Hande K.R., Noone R.M., Stone W.J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47–56.
    1. Chung W.H., Chang W.C., Stocker S.L., Juo C.G., Graham G.G., Lee M.H. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74(12):2157–2164.
    1. Ko T.M., Tsai C.Y., Chen S.Y., Chen K.S., Yu K.H., Chu C.S. Use of HLA-B∗58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015;351:h4848.
    1. Dalbeth N., Kumar S., Stamp L., Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):1646–1650.
    1. Stamp L.K., O'Donnell J.L., Zhang M., James J., Frampton C., Barclay M.L. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412–421.
    1. Juge P.A., Truchetet M.E., Pillebout E., Ottaviani S., Vigneau C., Loustau C. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2016
    1. Chou H.Y., Chen C.B., Cheng C.Y., Chen Y.A., Ng C.Y., Kuo K.L. Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS) J Clin Pharm Ther. 2015;40(6):689–692.
    1. Bardin T., Chales G., Pascart T., Flipo R.M., Korng Ea H., Roujeau J.C. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83(3):314–317.
    1. MacDonald T.M., Ford I., Nuki G., Mackenzie I.S., De Caterina R., Findlay E. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354.
    1. Gutman A.B., Yu T.F. Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis. Trans Assoc Am Physicians. 1951;64:279–288.
    1. Pui K., Gow P.J., Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013;40(6):872–876.
    1. Perez-Ruiz F., Alonso-Ruiz A., Calabozo M., Herrero-Beites A., Garcia-Erauskin G., Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545–549.
    1. Perez-Ruiz F., Calabozo M., Fernandez-Lopez M.J., Herrero-Beites A., Ruiz-Lucea E., Garcia-Erauskin G. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 1999;5(2):49–55.
    1. Bardin T., Keenan R.T., Khanna P.P., Kopicko J., Fung M., Bhakta N. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) Ann Rheum Dis. 2016
    1. Saag K.G., Fitz-Patrick D., Kopicko J., Fung M., Bhakta N., Adler S. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study) Arthritis Rheumatol. 2017;69(1):203–212.
    1. Takahashi S., Moriwaki Y., Yamamoto T., Tsutsumi Z., Ka T., Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572–575.
    1. Milionis H.J., Kakafika A.I., Tsouli S.G., Athyros V.G., Bairaktari E.T., Seferiadis K.I. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635–640.
    1. Richette P., Briere C., Hoenen-Clavert V., Loeuille D., Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol. 2007;34(10):2093–2098.
    1. Sundy J.S., Baraf H.S., Yood R.A., Edwards N.L., Gutierrez-Urena S.R., Treadwell E.L. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306(7):711–720.
    1. Vallon V., Thomson S.C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–225.
    1. Strauss M.B. Little Brown & Co.; USA: 1968. Familiar medical quotations.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다